Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study on the glucocorticoid [corticosteroid]-sparing effects of tocilizumab among glucocorticoid-dependent patients with adult Still's disease and systemic juvenile idiopathic arthritis: the open trial.

Trial Profile

Study on the glucocorticoid [corticosteroid]-sparing effects of tocilizumab among glucocorticoid-dependent patients with adult Still's disease and systemic juvenile idiopathic arthritis: the open trial.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Oct 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Adult-onset Still's disease; Juvenile rheumatoid arthritis
  • Focus Therapeutic Use

Most Recent Events

  • 15 Jan 2010 Actual initiation date (Jul 2008) added as reported by University Hospital Medical Information Network - Japan.
  • 15 Jan 2010 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
  • 16 Jul 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top